ArticleFrontiers in immunology2022

Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.

Carmen Mestre-Durán et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.